| Jul 15 |
Lexeo stock drops 24% amid Friedreich Ataxia study results
|
| Jul 15 |
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
|
| Jul 15 |
Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
|
| Jul 15 |
Lexeo gene therapy shows signs of heart benefit in small study
|
| Jul 15 |
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
|
| Jul 11 |
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
|
| Jul 8 |
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
|
| Jun 13 |
Companies Like Lexeo Therapeutics (NASDAQ:LXEO) Are In A Position To Invest In Growth
|
